Citi upgrades BioMarin Pharmaceutical Inc (Nasdaq: BMRN) from Hold to Buy based on valuation. Price target $17.

Citi analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE